Subscribe
shutterstock_1010946472_nitpicker-2
nitpicker / Shutterstock.com
1 July 2020Big Pharma

Chiesi blocks Japanese drugmaker’s new brand at EU General Court

Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker  Chiesi Farmaceutici.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

More on this story

Biotechnology
Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing
8 March 2022   Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.
Europe
Teva to face inhaler infringement allegations in UK court
3 June 2020   Israeli generic drugmaker Teva Pharmaceuticals must face infringement claims related to an asthma inhaler, an English judge has ruled.
Generics
EC plans to lower barriers to generic drugs
25 November 2020   The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York